These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Kaplan AP; Giménez-Arnau AM; Saini SS Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988 [TBL] [Abstract][Full Text] [Related]
8. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Giménez-Arnau AM Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304 [TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature. Tonacci A; Billeci L; Pioggia G; Navarra M; Gangemi S Pharmacotherapy; 2017 Apr; 37(4):464-480. PubMed ID: 28226418 [TBL] [Abstract][Full Text] [Related]
10. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Holm JG; Agner T; Sand C; Thomsen SF Int J Dermatol; 2017 Jan; 56(1):18-26. PubMed ID: 27337170 [TBL] [Abstract][Full Text] [Related]
11. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C Front Immunol; 2019; 10():1919. PubMed ID: 31474990 [TBL] [Abstract][Full Text] [Related]
12. The use of anti-IgE therapy beyond allergic asthma. Stokes JR; Casale TB J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342 [TBL] [Abstract][Full Text] [Related]
13. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report. Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab: not only for asthma. Ben-Shoshan M Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009 [TBL] [Abstract][Full Text] [Related]
17. Omalizumab may not inhibit mast cell and basophil activation in vitro. Gericke J; Ohanyan T; Church MK; Maurer M; Metz M J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818 [TBL] [Abstract][Full Text] [Related]
18. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723 [TBL] [Abstract][Full Text] [Related]
19. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. Metz M; Ohanyan T; Church MK; Maurer M J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603 [TBL] [Abstract][Full Text] [Related]
20. The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan. Chen T; Chan S; Lack G; Cro S; Cornelius VR Trials; 2017 May; 18(1):231. PubMed ID: 28535776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]